(Q83140055)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

metastatic breast cancer

1 reference

Naoki Hayashi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Seigo Nakamura

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hiroshi Yagata

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Yuji Shimoda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hidekazu Ota

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Gabriel N Hortobagyi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Massimo Cristofanilli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Naoto T Ueno

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

6 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

596-600

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

19 January 2020

cites work

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study

1 reference

12 December 2020

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Follow-up study of HER-2/neu amplification in primary breast cancer.

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

12 December 2020

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

1 reference

12 December 2020

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis

1 reference

12 December 2020

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

12 December 2020

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

1 reference

12 December 2020

Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan.

1 reference

12 December 2020

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

1 reference

12 December 2020

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

1 reference

12 December 2020

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

1 reference

12 December 2020

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

12 December 2020

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

1 reference

12 December 2020

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

12 December 2020

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

1 reference

12 December 2020

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

12 December 2020

Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.

1 reference

12 December 2020

Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.

1 reference

12 December 2020

Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden

1 reference

12 December 2020

10.1007/S10147-010-0173-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21210173%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference